DBiotherapeutics
- Biotech or pharma, therapeutic R&D
Next-Generation Approach:
D Biotherapeutics’ drug candidate, DBT178, is a highly potent, fully synthetic, protease-resistant, D-peptide-based inhibitor of TNF-alpha designed for oral administration.
DBT178 is stable in the GI-tract following oral administration, resulting in significant gut tissue levels in animal studies as well as systemic distribution. DBT178 proved non-immunogenic in NHP and therefore is less likely to be affected by anti-drug antibodies which drive secondary loss of response for anti-TNF biologics. Studies performed to date include in vitro and in vivo validation, rodent, dog and NHP PK assessments and NHP exploratory toxicology.
DBT178 is now advancing to GLP toxicology studies and IND filing.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}